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Background." Prilocaine-lidocaine emulsion (EMLA) has been used successfully as a 
local anesthetic npatients undergoing superficial procedures. 
Objective: The purpose of this study was to investigate the analgesic effect of the patch as 
a local anesthetic for children undergoing a skin biopsy procedure. The effect on both the 
pain at the injection site and the pain of the biopsy was investigated. 
Methods: The study was randomized, double blinded, an  placebo controlled. Of the 63 
children randomly recruited into the study, 60 children were evaluated; the remaining 
three were withdrawn from the study. 
Results: The anesthetic patch was significantly more effective than the placebo patch in 
decreasing pain at the injection site. No significant difference inpain scores of the biop- 
sy procedure was found between the study groups. No serious ide effects were observed. 
Conclusion: The anesthetic patch reduced the pain experienced bychildren subjected to 
a skin biopsy procedure. 
(J Am Acad Dermatol 1997;37:418-21.) 
A skin biopsy procedure usually requires the 
infiltration of a local anesthetic, a process that 
itself is often painful and causes anxiety. Use of 
topical prilocaine-lidocaine cream (EMLA) as a 
local anesthetic has been successful in patients 
undergoing superficial procedures such as 
venipuncture, lumbar punctures, and curettage of 
mollusca contagiosa. 1-5 Use of this cream as a 
local anesthetic in patients undergoing a skin 
biopsy procedure has been examined. In a study of 
12 adult volunteers, the maximal depth of anes- 
thesia achieved with use of the cream was 5 ram; 
this depth was reached 30 minutes after applica- 
tion of the cream for 90 minutes and 60 minutes 
after application for 120 minutes. 6 In another 
study, 10 patients reported pain deep in the dermis 
during a skin biopsy procedure after application of 
the cream. 7 In a study by Jones et al., s a 60-minute 
application of cream was not effective in elimi- 
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nating the pain caused by injection of a local anes- 
thetic in 60 adult patients. To enhance the ease of 
application, a single unit dose package of lido- 
caine/prilocaine 5% emulsion has been devel- 
oped, which might eliminate the possibility of 
incorrect application that leads to lack of anal- 
gesic effect. In a study of 108 adults undergoing 
either excisional biopsy procedures or curettage 
with electrosurgery, EMLA cream (Tegaderm) 
and patch formulations were shown to be equally 
effective9; this study also showed that the cream 
provided effective anesthesia n 87% of subjects 
after application for 110 to 180 minutes. 
No reports exist of serious ide effects after appli- 
cation of the anesthetic emulsion, although a tem- 
porary local redness or paleness of the skin may 
occur. 
The purpose of this study was to investigate the 
analgesic effect of the patch as a local anesthetic 
for children undergoing a skin biopsy procedure. 
The effect on both the pain at the injection site and 
the pain of the biopsy was investigated. We also 
evaluated the differences in pain experienced by 
boys and girls. 
MATERIAL AND METHODS 
The protocol for the study was approved by the 
Medical Ethical Committee of the University Hospital 
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Table I. Statistical analysis of the difference in VAS scores after the injection and the biopsy between 
the EMLA group and the placebo~group 
Injection Biopsy 
EMLA Placebo EMLA Placebo 
Median 0.80 2.80 0 0 
IQR 0.13-2.25 1.23-6.65 0-0.45 0-2.03 
Mann-Whitney 0.002 0.142 
test p value 
]QR, Interquartile range. 
Table II. Distribution of the verbal pain scores of the patients and the physician and statistical nalysis of 
the difference in verbal pain scores after the injection and the biopsy between the EMLA group and the 
plalacebo group 
Injection Biopsy 
Patient Physician Patient Physician 
EMLA Placebo EMLA Placebo EMLA Placebo EMLA Placebo 
No pain 8 3 
Mild pain 16 14 
Moderate pain 3 8 
Severe pain 1 7 
Exact-trend 0.004 
test p value 
12 4 24 21 23 26 
13 15 1 7 5 5 
3 10 3 3 0 1 
0 3 0 1 0 0 
0.001 0.226 0.781 
Rotterdam. The study group consisted of chil ren who 
required a skin biopsy procedure for investigation of a 
skin disorder. The children's parents gave signed 
informed consent after they had received verbal and 
written information about the study. 
The study was randomized, double blinded, and 
placebo controlled. Two parallel groups were used; 31 
children received an EMLA patch and 32 children 
received a placebo patch at he site of the biopsy for 60 
minutes. After removal of the patch the physician 
examined the skin for side effects and then infiltrated 
the skin with 1 ml of lidocaine and performed th  biop- 
sy with a 4 mm punch. 
The child and the physician indicated the level of 
pain on a verbal scale as "no pain," mild pain," mod- 
erate pain," or "severe pain." The child also indicated 
the level of pain on a 10 mm ungraded line (visual ana- 
logue scale [VAS]). An indication of 0 mm represented 
"no pain" and 10 mm represented "the worst pain you 
can imagine." The VAS is used extensively and is con- 
sidered to be as reliable as an objective pain score. It is 
suitable for use with subjects 4 years of age and 
older. 1°,11 The pain was scored after the lidocaine was 
injected and after the biopsy was performed. 
The difference in the distribution of pain scores 
between groups was tested with use of the Mann- 
Whitney test for the VAS scores because of their posi- 
five skewness. The four-point verbal pain scores were 
compared between groups in a 4 x 2 cross table and 
tested with use of an exact-trend test. 
RESULTS 
Sixty-three children were randomly recruited 
into the study. Three children were withdrawn 
from the study because two had excessive anxiety 
and scores were missing for one child. Thus 60 
children were evaluated. 
The study included 29 girls (15 in the EMLA 
group and 14 in the placebo group) and 31 boys 
(13 in the EMLA group and 18 in the placebo 
group). The age of the subjects varied from 4 
years to 15 years (mean, 9.6 years) in the EMLA 
group and from 4 years to 18 years (mean, 8.5 
years) in the placebo group. The groups were bal- 
anced with regard to the ages and gender of the 
subjects. 
Tables I and II show the characteristics of the 
distributions of the VAS pain scores and verbal 
pain scores for the injection and for the biopsy in 
the EMLA group and the placebo group. The dis- 
tribution of VAS pain scores for the injection in 
the EMLA group was significantly lower than in 
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the placebo group (z = 3.06; p = 0.002). The VAS 
scores for the biopsy did not show a significant 
difference (z = 1.47; p = 0.142). 
A significant difference xisted between both 
treatment groups in the distribution of the verbal 
pain scores for the injection scored by the patient 
and by the physician. In the EMLA group the ver- 
bal pain scores were significantly lower (p = 
0.004 respectively p = 0.001, two-sided, exact- 
trend test). In the distribution of verbal pain scores 
of the biopsy no significant difference existed 
between the EMLA and the placebo groups. 
A difference in pain scoring was noted between 
boys and girls in the EMLA and placebo groups. 
In the placebo group the girls scored significantly 
higher on the VAS scores of the injection than did 
the boys (z = 2.11; p = 0.035). In this group there 
was no difference in VAS scores of the biopsy. In 
the EMLA group the girls scored higher on the 
VAS than the boys, although the difference was 
not significant (injection: z = 1.69, p = 0.091; 
biopsy: z = 1.85, p = 0.065). 
On the verbal scales of the patient and the 
physician for the injection in the EMLA group, 
the girls scored significantly higher than the boys 
(p = 0.017 resp. p = 0.044, two-sided, exact-trend 
test). The other verbal scores showed a trend of 
girls scoring higher than boys, but the differences 
were not significant. 
No serious side effects were observed in any of 
the children. 
DISCUSSION 
The results of this study showed that the anes- 
thetic patch significantly reduced the pain at the 
site of lidocaine infiltration before a skin biopsy 
procedure was performed in children. 
Thune et al. 12 compared use of the anesthetic 
cream and infiltration with prilocaine in 51 adults. 
The cream was an effective local anesthetic after 
a mean application time of 2 hours. After a short- 
er application time, and in the case of a large biop- 
sy site (mean area, 10 cm 2) in several patients, 
prilocaine infiltration was necessary after the 
cream application to obtain adequate anesthesia. 12
Jones et al. 8 showed that the anesthetic ream 
was not effective in eliminating pain on injection 
of the local anesthetic when it was applied for 1 
hour in 60 adults. They suggested that a longer 
application could improve the analgesic effect, but 
this would limit its use for routine procedures. 
Gupta and Sibbald 9found that the cream provided 
effective anesthesia n 87% of patients after appli- 
cation for 110 to 180 minutes. 
The anesthetic ream may be a useful local 
anesthetic for children undergoing kidney biopsy 
procedures. Ogborn 13 reported that the cream was 
used as a substitute for dermal infiltration of local 
anesthetic for eight children who underwent a per- 
cutaneous kidney biopsy procedure. Five children 
reported no sensation of the initial skin puncture. 
Only one child felt "a sharp object." 
In our study no difference xisted in the pain 
scores of the EMLA and placebo groups for the 
biopsy. This is not surprising because infiltration 
with lidocaine, although painful itself, provides 
adequate anesthesia. All children received lido- 
caine infiltration after removal of the patch. 
In our study girls appeared to experience more 
pain than boys. This finding corroborates our obser- 
vations in a previous tudy on use of the cream as a 
local anesthetic in mumps/measles/rubella (MMR) 
vaccination in children (manuscript submitted for 
publication). In contrast, Taddio et al. 14 reported a
lower pain score in girls than in boys. 
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CALL FOR PATIENTS WITH INHERITED DISEASES OF THE SKIN 
We in San Francisco as well as skin biologists in other cities are interested in find- 
ing the chromosomal location and eventually identifying the genes whose abnormali- 
ties underlie several inherited diseases of the skin. Initially, the group believes diseases 
for which this strategy offers the most likely insights include several disordors of ker- 
atinization (ichthyoses, Darier's disease, and Halley-Halley disease), several forms of 
epidermolysis bullosa, several forms of Ehlers-Danlos yndrome, psoriasis, atopic der- 
matitis, and keloids. Indeed, ongoing studies of several such diseases have already 
been fruitful. 
We are eager to identify kindreds with these conditions--larger kindreds for the 
more common disorders (e.g., psoriasis, atopic dermatitis), and smaller as well as larg- 
er kindreds for the less common disorders (e.g., Darier's disease). I f  you know of such 
a kindred, please contact Ervin Epstein, Jr., MD, Room 269, Bldg. 100, 1001 Potrero 
St., San Francisco, CA 94110; telephone: 1-800-285-1267; fax: (415)282-5998. 
Investigators interested in collaborating more actively in such a linkage analysis at 
either the clinical or the laboratory level also are most welcome to contact Dr. Epstein. 
